Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Cindy Devone-Pacheco

Payer Advocacy: The CORC/ISC Is Working for Your Practice

Douglas White, MD  |  October 31, 2017

One of the least recognized, most important (certainly for rheumatologists in the U.S. running their own practice), and hardest working committees at the ACR is the Insurance Subcommittee (ISC). Currently chaired by Sean Fahey, MD, and managed by ACR staff liaison Meredith Strozier, this group of dedicated volunteers monitors the insurance landscape, fields complaints from…

Judge Rejects Bid by 18 U.S. States to Revive Obamacare Subsidies

Dan Levine and Lawrence Hurley  |  October 27, 2017

SAN FRANCISCO/WASHINGTON (Reuters)—A U.S. judge on Wednesday refused to block President Donald Trump’s decision to end subsidy payments to health insurers under Obamacare, handing Trump a victory against Democratic attorneys general who have regularly challenged the president’s policies in court. U.S. District Judge Vince Chhabria in San Francisco said the federal government did not have…

Americans Want to See a Bipartisan Fix for Obamacare

Jilian Mincer and Chris Kahn  |  October 27, 2017

NEW YORK (Reuters)—As Republican and Democratic lawmakers clash over the future of Obamacare, Americans largely are eager for a bipartisan solution to its shortcomings, according to a Reuters/Ipsos opinion poll released on Thursday. The Oct. 14-23 poll found that 62 percent of Americans want former President Barack Obama’s healthcare law to be maintained, up from…

Billionaire Insys Founder Charged in U.S. Opioid Bribe Case

Nate Raymond  |  October 27, 2017

BOSTON (Reuters)—The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic. John Kapoor, Insys’ majority shareholder who stepped down as chief executive in January, was charged…

Trump Declares Opioids a U.S. Public Health Emergency

Yasmeen Abutaleb and Jeff Mason  |  October 27, 2017

WASHINGTON (Reuters)—U.S. President Donald Trump declared the opioid crisis a public health emergency on Thursday, stopping short of a national emergency declaration he promised months ago that would have freed up more federal money. Responding to a growing problem wreaking havoc in rural areas, Trump’s declaration will redirect federal resources and loosen regulations to combat…

U.S. Scientists Unveil Powerful New Tools to Fix Genetic Faults

Julie Steenhuysen  |  October 26, 2017

CHICAGO (Reuters)—U.S. scientists on Wednesday unveiled two new molecular editing tools designed to fix mutations that cause the majority of human genetic diseases, some of which have no known treatment. One technique, by David Liu of Harvard University and the Broad Institute of MIT and Harvard, offers a highly precise way to fix single-letter mistakes…

U.S. to Promote Use of Opioid Alternatives to Treat Addiction

Toni Clarke  |  October 26, 2017

(Reuters)—The U.S. Food and Drug Administration plans to encourage opioid addicts to use less harmful opioid drugs such as methadone and buprenorphine, a radical shift in policy that could agitate those in the addiction field who believe abstinence is the only effective treatment. Speaking before the House Committee on Energy and Commerce on Wednesday, FDA…

Rhode Island Doctor Pleads Guilty to Opioid Kickback Scheme

Nate Raymond  |  October 26, 2017

BOSTON (Reuters)—A Rhode Island doctor pleaded guilty on Wednesday to charges he participated in a scheme to obtain kickbacks in exchange for writing prescriptions for an addictive fentanyl-based cancer pain drug produced by Insys Therapeutics Inc. The plea by Jerrold Rosenberg came amid ongoing investigations of Insys related to Subsys, an under-the-tongue spray that contains…

More Republican U.S. Senators Back Bipartisan Obamacare Deal

Richard Cowan and Yasmeen Abutaleb  |  October 22, 2017

WASHINGTON (Reuters)—A bipartisan deal to stabilize Obamacare by restoring billions of dollars of federal subsidies to health insurers picked up Republican support in the Senate on Thursday despite President Donald Trump’s opposition but still faced an uphill battle. Republican Senator Lamar Alexander and Democratic Senator Patty Murray formally introduced legislation to shore up the insurance…

Novartis to Shut U.S. Generics Plant, Cut 450 Jobs

Reuters Staff  |  October 19, 2017

ZURICH (Reuters)—Swiss drugmaker Novartis is to cut 450 jobs in the United States over the next two years as it gradually shuts a generics manufacturing plant in Colorado and discontinues some products in the face of intense price pressures. “To remain competitive in the U.S., Novartis will discontinue or divest limited growth products in saturated…

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 28
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences